Greenrose Acquisition Corp. (GNRSW)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Greenrose Acquisition Corp. (GNRSW) with AI Score 43/100 (Weak). Greenrose Holding Company Inc. focuses on the production and sale of cannabis products, including cultivation, processing, and packaging of medical cannabis and derivative products. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 18, 2026Greenrose Acquisition Corp. (GNRSW) Healthcare & Pipeline Overview
Greenrose Holding Company Inc. cultivates, processes, and packages medical cannabis and derivative products, positioning itself within the specialty and generic drug manufacturing segment of the healthcare sector. Founded in 2014, the company aims to serve the growing demand for medical cannabis products amidst evolving regulations and market dynamics.
Investment Thesis
Greenrose Holding Company Inc. presents a speculative investment opportunity within the evolving cannabis industry. With a market capitalization of $0.00B and a high beta of 3309.14, the stock demonstrates significant volatility. The company's reported profit margin of 70.6% and gross margin of 59.1% suggest potential profitability, but these figures need to be validated with consistent performance over time. Growth catalysts include the expansion of legal cannabis markets and the development of new cannabis-based products. However, the company faces risks related to regulatory uncertainty, competition, and the challenges of operating in the OTC market. Investors should carefully assess the company's financial stability, operational efficiency, and ability to navigate the complex regulatory landscape before considering an investment. The lack of a dividend yield reflects a focus on reinvesting earnings for growth.
Based on FMP financials and quantitative analysis
Key Highlights
- Profit Margin of 70.6% indicates strong potential profitability, though it needs to be sustained over time.
- Gross Margin of 59.1% suggests efficient cost management in the production and sale of cannabis products.
- Beta of 3309.14 indicates extremely high volatility compared to the broader market.
- Market Cap of $0.00B reflects the company's small size and potential for growth or instability.
- The company does not offer a dividend, suggesting a focus on reinvesting earnings for future expansion.
Competitors & Peers
Strengths
- Vertically integrated operations.
- High profit margin (70.6%).
- Established presence in specific markets.
- Focus on medical cannabis.
Weaknesses
- OTC listing indicates higher risk and lower liquidity.
- High beta (3309.14) indicates extreme volatility.
- Small market capitalization ($0.00B).
- Limited financial information available.
Catalysts
- Upcoming: Potential changes in cannabis regulations at the state or federal level could create new market opportunities.
- Ongoing: Expansion of the company's product line to include new cannabis-based therapies.
- Ongoing: Strategic partnerships with other companies in the cannabis industry to expand market reach.
- Upcoming: Positive results from clinical trials of the company's cannabis-based products.
- Ongoing: Increasing acceptance and legalization of cannabis for medical purposes.
Risks
- Potential: Regulatory uncertainty and changes in cannabis laws could negatively impact the company's operations.
- Ongoing: Intense competition from other cannabis producers could erode market share and profitability.
- Potential: Price volatility in the cannabis market could impact the company's revenue and earnings.
- Ongoing: Challenges of operating in the OTC market, including limited liquidity and disclosure requirements.
- Potential: Negative publicity or reputational damage could harm the company's brand image.
Growth Opportunities
- Expansion into New Markets: As more states and countries legalize cannabis for medical or recreational use, Greenrose has the opportunity to expand its geographic reach. This includes establishing cultivation and distribution facilities in new markets, either organically or through acquisitions. The global legal cannabis market is projected to reach $42.7 billion by 2027, presenting a significant opportunity for Greenrose to increase its revenue and market share. Timeline: Ongoing, dependent on regulatory changes and market entry strategies.
- Product Innovation and Development: Greenrose can invest in research and development to create new and innovative cannabis-based products, such as novel formulations, delivery methods, or therapeutic applications. This can help the company differentiate itself from competitors and capture a larger share of the market. The market for cannabis-infused products is growing rapidly, with consumers seeking new and convenient ways to consume cannabis. Timeline: Ongoing, with new products potentially launching within the next 1-3 years.
- Strategic Partnerships and Acquisitions: Greenrose can pursue strategic partnerships or acquisitions to expand its capabilities, access new markets, or consolidate its position in existing markets. This could include partnering with other cannabis companies, pharmaceutical companies, or research institutions. The cannabis industry is undergoing consolidation, with larger companies acquiring smaller players to gain scale and market share. Timeline: Ongoing, with potential deals occurring within the next 1-2 years.
- Development of Branded Products: Creating strong, recognizable brands can help Greenrose build customer loyalty and differentiate itself from competitors. This includes investing in marketing, advertising, and packaging to create a consistent brand image. The cannabis market is becoming increasingly brand-conscious, with consumers seeking out trusted and reputable brands. Timeline: Ongoing, with brand development efforts continuing over the next several years.
- Focus on Medical Cannabis: Greenrose can focus on the medical cannabis market, which offers higher margins and greater regulatory certainty compared to the recreational market. This includes developing cannabis-based therapies for specific medical conditions and working with healthcare professionals to promote their use. The medical cannabis market is expected to continue to grow as more research supports the therapeutic benefits of cannabis. Timeline: Ongoing, with a focus on clinical trials and regulatory approvals over the next 3-5 years.
Opportunities
- Expansion into new legal cannabis markets.
- Development of new cannabis-based products.
- Strategic partnerships and acquisitions.
- Growing demand for medical cannabis.
Threats
- Regulatory uncertainty and changes in cannabis laws.
- Intense competition from other cannabis producers.
- Price volatility in the cannabis market.
- Challenges of operating in the OTC market.
Competitive Advantages
- Vertically integrated operations provide cost control and quality assurance.
- Proprietary cultivation and processing techniques.
- Established relationships with dispensaries and retailers.
- Brand recognition in specific markets.
About GNRSW
Greenrose Holding Company Inc., established in 2014 and headquartered in Amityville, New York, operates in the cannabis industry through its subsidiaries. The company focuses on the production and sale of cannabis products, specifically engaging in the cultivation, processing, and packaging of medical cannabis and derivative products. This includes a range of cannabis-based medications and related items aimed at addressing various medical needs. The company's business model centers around vertically integrated operations, controlling the process from cultivation to final product distribution. This allows Greenrose to maintain quality control and potentially capture higher margins throughout the value chain. Greenrose's products are targeted towards patients and consumers in jurisdictions where medical cannabis is legal. The company navigates a complex regulatory environment, adhering to state and local laws governing cannabis production and sales. Greenrose aims to expand its market presence and product offerings, capitalizing on the increasing acceptance and legalization of cannabis for medical purposes. The company faces competition from other cannabis producers and pharmaceutical companies exploring cannabis-based therapies. Greenrose’s success depends on its ability to efficiently manage its operations, innovate in product development, and adapt to the changing regulatory landscape.
What They Do
- Cultivates medical cannabis.
- Processes raw cannabis into usable forms.
- Packages cannabis products for distribution.
- Sells medical cannabis products to patients and consumers.
- Develops derivative cannabis products.
- Operates in jurisdictions where medical cannabis is legal.
Business Model
- Vertically integrated operations from cultivation to distribution.
- Focus on medical cannabis products.
- Sales through dispensaries and other retail channels.
- Revenue generated from the sale of cannabis products.
Industry Context
Greenrose Holding Company Inc. operates within the rapidly evolving cannabis industry, which is experiencing significant growth due to increasing legalization and acceptance of cannabis for medical and recreational purposes. The market is characterized by intense competition, with numerous companies vying for market share. Greenrose competes with both established cannabis producers and pharmaceutical companies exploring cannabis-based therapies. The industry is subject to complex and changing regulations, which pose challenges and opportunities for companies like Greenrose. The global legal cannabis market is projected to reach billions of dollars in the coming years, presenting significant growth potential for companies that can navigate the regulatory landscape and establish a strong market position.
Key Customers
- Patients with medical conditions that qualify for medical cannabis use.
- Consumers in jurisdictions where recreational cannabis is legal.
- Dispensaries and retail stores that sell cannabis products.
- Healthcare professionals who recommend medical cannabis to their patients.
Financials
Chart & Info
Greenrose Acquisition Corp. (GNRSW) stock price: Price data unavailable
Latest News
No recent news available for GNRSW.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GNRSW.
Price Targets
Wall Street price target analysis for GNRSW.
MoonshotScore
What does this score mean?
The MoonshotScore rates GNRSW's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Nicole Conboy
CEO
Nicole Conboy serves as the CEO of Greenrose Holding Company Inc. Information regarding her detailed career history, education, and previous roles is not available in the provided data. Therefore, a comprehensive background profile cannot be constructed. Further research would be required to ascertain her specific qualifications and experience in the cannabis industry or related fields.
Track Record: Due to the limited information available, it is not possible to assess Nicole Conboy's track record at Greenrose Holding Company Inc. or in previous roles. Key achievements, strategic decisions, and company milestones under her leadership cannot be determined based on the provided data. Further research would be necessary to evaluate her performance and contributions to the company.
GNRSW OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Greenrose Holding Company Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in GNRSW.
- Low trading volume and liquidity can lead to price volatility.
- OTC listing indicates a higher risk profile compared to major exchanges.
- Regulatory uncertainty in the cannabis industry adds to the risk.
- Potential for price manipulation due to limited oversight.
- Verify the company's financial statements and audit reports.
- Research the company's management team and their experience.
- Assess the company's competitive position in the cannabis market.
- Evaluate the company's compliance with regulatory requirements.
- Understand the risks associated with investing in OTC stocks.
- Monitor trading volume and price movements closely.
- Consult with a financial advisor before investing.
- The company has been in operation since 2014.
- It is involved in the production and sale of cannabis products.
- The company has a reported profit margin of 70.6%.
- The company employs 91 people.
Greenrose Acquisition Corp. Stock: Key Questions Answered
What does Greenrose Acquisition Corp. do?
Greenrose Holding Company Inc., through its subsidiaries, cultivates, processes, and sells cannabis products, primarily focusing on medical cannabis and derivative products. The company operates in the healthcare sector, specifically within the specialty and generic drug manufacturing segment. Its core activities include cultivating cannabis plants, processing them into various forms suitable for medical use, packaging the products, and distributing them through legal channels. Greenrose aims to capitalize on the growing demand for medical cannabis while adhering to regulatory requirements.
What do analysts say about GNRSW stock?
There is no available analyst consensus on GNRSW stock. Given its OTC listing and limited information, comprehensive analyst coverage is unlikely. Key valuation metrics such as price targets and ratings are not readily available. Investors should rely on their own due diligence and risk assessment when considering an investment in GNRSW. The company's growth potential is tied to the expansion of the legal cannabis market, but significant risks remain due to regulatory uncertainty and competition.
What are the main risks for GNRSW?
The primary risks for Greenrose Holding Company Inc. include regulatory uncertainty in the cannabis industry, intense competition from other cannabis producers, and the challenges of operating in the OTC market. Changes in cannabis laws at the state or federal level could significantly impact the company's operations and profitability. The OTC listing indicates higher risk and lower liquidity compared to major exchanges. Investors should carefully assess these risks before investing in GNRSW.
What are the key factors to evaluate for GNRSW?
Greenrose Acquisition Corp. (GNRSW) currently holds an AI score of 43/100, indicating low score. Key strength: Vertically integrated operations.. Primary risk to monitor: Potential: Regulatory uncertainty and changes in cannabis laws could negatively impact the company's operations.. This is not financial advice.
How frequently does GNRSW data refresh on this page?
GNRSW prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven GNRSW's recent stock price performance?
Recent price movement in Greenrose Acquisition Corp. (GNRSW) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Vertically integrated operations.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider GNRSW overvalued or undervalued right now?
Determining whether Greenrose Acquisition Corp. (GNRSW) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying GNRSW?
Before investing in Greenrose Acquisition Corp. (GNRSW), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on the company's financials and operations.
- OTC listing indicates higher risk and lower liquidity.
- Analyst coverage is limited due to the company's size and OTC listing.